TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28327905

Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg two times daily (increased to 300 mg two times daily at disease progression)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 25
Study: 28327908

Group type: EXPERIMENTAL
Intervention: Predicted plasma 25(OH)D score (highest quintile)
Number of subjects: 1016
Study: 28327953

Group type: EXPERIMENTAL
Intervention: First-line everolimus followed by second-line sunitinib
Number of subjects: 471

Group type: COMPARATOR
Intervention: First-line sunitinib followed by second-line everolimus
Number of subjects: 471
Study: 28327958

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (ASCT)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Validation in an independent sample of 389 patients
Number of subjects: 1045
Study: 28327988

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC)
Number of subjects: 42
Study: 28328966

Group type: EXPERIMENTAL
Intervention: Integration of family planning (FP) services into HIV care clinics at six delayed integration clinics.
Number of subjects: 5682

Group type: EXPERIMENTAL
Intervention: Early integration of FP and HIV services at twelve early integration sites.
Number of subjects: 5682

Group type: COMPARATOR
Intervention: All 18 integrated sites in year two.
Number of subjects: 5682
Study: 28329053

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 28329198

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 101
Study: 28329286

Group type: EXPERIMENTAL
Intervention: MGN1703 (60 mg subcutaneously twice weekly for 4 weeks)
Number of subjects: 15
Study: 28329385

Group type: EXPERIMENTAL
Intervention: Combined left atrial volume index (LAVI) >40 ml/m2 and tricuspid regurgitation (TR) >3.1 m/s
Number of subjects: 237
Study: 28329393

Group type: EXPERIMENTAL
Intervention: Second-line ART based on ritonavir-boosted lopinavir combined with zidovudine or tenofovir plus lamivudine or emtricitabine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tuberculosis treatment
Number of subjects: 101
Study: 28330462

Group type: EXPERIMENTAL
Intervention: Everolimus, administered orally at a daily dose of 10 mg continuously (28-day cycles).
Number of subjects: 10
Study: 28330651

Group type: EXPERIMENTAL
Intervention: Fusion of IVUS and OCT imaging
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: OCT imaging
Number of subjects: 72
Study: 28330670

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for evaluating CAV severity
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of LFP and bright spots
Number of subjects: 62
Study: 28330907

Group type: EXPERIMENTAL
Intervention: Plasma ω-3 fatty acids
Number of subjects: 0
Study: 28331015

Group type: EXPERIMENTAL
Intervention: Clinically recorded alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28331539

Group type: EXPERIMENTAL
Intervention: Ramosetron 5 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28331611

Group type: EXPERIMENTAL
Intervention: One ultrasound-guided high-intensity focused ultrasound (HIFU) treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two ultrasound-guided high-intensity focused ultrasound (HIFU) treatments
Number of subjects: 20
Study: 28331623

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA)
Number of subjects: 47
Study: 28331988

Group type: EXPERIMENTAL
Intervention: Point-of-care testing of cardiac autonomic function by means of short-term deceleration capacity (DC) of heart rate
Number of subjects: 1821
Study: 28332144

Group type: EXPERIMENTAL
Intervention: IDegLira in DUAL I (n=1663) vs. insulin degludec or liraglutide 1.8 mg; 52 weeks
Number of subjects: 379

Group type: COMPARATOR
Intervention: IDegLira in DUAL IV (n=435) vs. placebo; 26 weeks
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: IDegLira in DUAL II (n=398) vs. insulin degludec; 26 weeks
Number of subjects: 379
Study: 28333699

Group type: EXPERIMENTAL
Intervention: sf-IL-6
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: C1M
Number of subjects: 104
Study: 28333704

Group type: EXPERIMENTAL
Intervention: High plasma:RBC ratio (≥1 plasma unit:1 RBC unit)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: High PLT:RBC ratio (≥0.2 PLT doses:1 RBC unit)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Low plasma:RBC ratio
Number of subjects: 324

Group type: COMPARATOR
Intervention: Low PLT:RBC ratio
Number of subjects: 324
Study: 28333976

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI) baseline cutoff of 150 ng/L
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI) change of 20 ng/L after 1 hour
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: 3-hours ESC algorithm
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: 1-hour ESC algorithm
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Additional application of an ischemic ECG
Number of subjects: 1516
Study: 28334685

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation or exercise
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Viral pathogen detected
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Influenza infections
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Early IP-10 concentration measurement
Number of subjects: 225
Study: 28335038

Group type: EXPERIMENTAL
Intervention: Integrated education intervention (INT)
Number of subjects: 530

Group type: COMPARATOR
Intervention: CVD-specific education intervention (C)
Number of subjects: 530
Study: 28335733

Group type: EXPERIMENTAL
Intervention: Short-term hyperoxia (2-hour exposure)
Number of subjects: 20
Study: 28335798

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneous daily (with escalation to 200 mg and 300 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Anakinra 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Anakinra 300 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Anakinra (all doses)
Number of subjects: 6
Study: 28335823

Group type: EXPERIMENTAL
Intervention: Clinical Readiness Consultation Tool (CRCT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pilot testing of the CRCT
Number of subjects: 53
Study: 28336527

Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg)
Number of subjects: 95
Study: 28336743

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic position (SEP) indicators such as fewer assets and having a daily wage labourer as the highest occupation.
Number of subjects: 165233

Group type: EXPERIMENTAL
Intervention: Low levels of education.
Number of subjects: 165233
Study: 28336780

Group type: EXPERIMENTAL
Intervention: Tau Tracer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28337155

Group type: EXPERIMENTAL
Intervention: Different e-Cigarette Generation and Models
Number of subjects: 0
Study: 28337324

Group type: EXPERIMENTAL
Intervention: GBT440 (dosage and duration not specified)
Number of subjects: 0
Study: 28337781

Group type: EXPERIMENTAL
Intervention: Conservative management (antithrombotic therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28338153

Group type: EXPERIMENTAL
Intervention: Different reconstruction methods for total gastrectomy
Number of subjects: 11872
Study: 28339149

Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride 15 mg twice daily before food
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride 15 mg twice daily after food
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tenapanor hydrochloride 15 mg twice daily while fasting
Number of subjects: 18
Study: 28339500

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 2933

Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 2933
Study: 28339607

Group type: EXPERIMENTAL
Intervention: Motor trajectories assessment using Alberta Infant Motor Scales at 4, 6, 9, and 12 months
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Motor trajectories predictive of 24-month cognitive and motor outcomes
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Logistic regression analyses for influencing factors
Number of subjects: 342
Study: 28339818

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CAVIAR response score
Number of subjects: 240
Study: 28340695

Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fraction injection
Number of subjects: 12

Group type: COMPARATOR
Intervention: Iloprost infusion (previously received by 8 patients)
Number of subjects: 12
Study: 28341300

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bortezomib and carboplatin (AUC 4 or 5) every 21 days for 6 cycles
Number of subjects: 33
Study: 28341306

Group type: EXPERIMENTAL
Intervention: High-frequency QRS (HFQRS) analysis
Number of subjects: 324

Group type: COMPARATOR
Intervention: Conventional ECG diagnosis by treating physician
Number of subjects: 324

Group type: COMPARATOR
Intervention: Conventional ECG diagnosis by expert cardiologist
Number of subjects: 324

Group type: COMPARATOR
Intervention: Automated computer program for ECG diagnosis
Number of subjects: 324
Study: 28341495

Group type: EXPERIMENTAL
Intervention: TMX-101 (200mg/50ml, 0.4%) administered intravesically for 6 weeks
Number of subjects: 12
Study: 28341686

Group type: EXPERIMENTAL
Intervention: Brain MRI incidental findings (IF)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Relevant white matter hyperintensities (WMH)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Vascular abnormalities
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Cysts
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Brain volume loss
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Neoplastic brain findings
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Correlation between age and IF
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Brain atrophy
Number of subjects: 575
Study: 28341957

Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin 30 mg/m² plus lapatinib
Number of subjects: 11
Study: 28342180

Group type: EXPERIMENTAL
Intervention: ART containing zidovudine
Number of subjects: 1166

Group type: COMPARATOR
Intervention: ART containing tenofovir disoproxil
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: NNRTI-based ART (both zidovudine and tenofovir)
Number of subjects: 1166
Study: 28342713

Group type: EXPERIMENTAL
Intervention: Laboratory score combining glucose, RDW, eGFR with hs-cTnT or hs-cTnI
Number of subjects: 1095

Group type: COMPARATOR
Intervention: hs-cTn alone using the limit of detection (LoD)
Number of subjects: 1095
Study: 28342989

Group type: EXPERIMENTAL
Intervention: DAA regimens
Number of subjects: 1600
Study: 28343143

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Number of subjects: 20
Study: 28343236

Group type: EXPERIMENTAL
Intervention: Chloride-limited fluid strategy (buffered salt solution and 20% albumin)
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Chloride-rich fluid strategy (0.9% saline and 4% albumin)
Number of subjects: 1136
Study: 28343449

Group type: EXPERIMENTAL
Intervention: Severe iron loading with very low T2* of 5.0 ± 2.0 ms (iron concentration 8.5 ± 7.0 mg/g dw) and diffuse granular myocardial iron deposition.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interstitial fibrosis quantified by computer using picrosirius red (PSR) staining expressed as collagen volume fraction (CVF).
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Severe cardiac siderosis and heart failure.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Replacement cardiac fibrosis.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Minor interstitial fibrosis.
Number of subjects: 10
Study: 28343763

Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitors with remote monitoring capabilities (SMART-MI trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy (REFINE-ICD trial)
Number of subjects: 0
Study: 28344643

Group type: EXPERIMENTAL
Intervention: TAU + GOLIAH (automated serious gaming platform, 4 sessions of 30 minutes per week at home and 1 session at hospital for 6 months)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: TAU + GOLIAH
Number of subjects: 14

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 14
Study: 28344793

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 5722

Group type: COMPARATOR
Intervention: Fecal Immunochemical Testing (FIT)
Number of subjects: 5722

Group type: EXPERIMENTAL
Intervention: Colonoscopy (primary and work-up)
Number of subjects: 5722
Study: 28345157

Group type: COMPARATOR
Intervention: 0.5 mg/day entecavir
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: 0.5 mg/day entecavir maleate
Number of subjects: 275
Study: 28345539

Group type: EXPERIMENTAL
Intervention: Moderate hyperglycemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severe hyperglycemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Euglycemia
Number of subjects: 0
Study: 28345951

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Number of subjects: 0
Study: 28346229

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation with gene-modified CD34+ cells (MND-ADA) after busulfan conditioning (90 mg/m2) and ERT cessation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation with gene-modified CD34+ cells (MND-ADA)
Number of subjects: 10
Study: 28346714

Group type: EXPERIMENTAL
Intervention: ELISA (>0.35 μg/ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OPA (>1:8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 30
Study: 28346737

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: CEUS
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: MRI + CT
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: CEUS as second imaging technique
Number of subjects: 442
Study: 28346762

Group type: EXPERIMENTAL
Intervention: Chronic pain (CP)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Persistent pain (PP)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Preoperative pain and higher postoperative opioid requirement
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Childhood Anxiety Sensitivity Index
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Surgical duration
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Anxiety scores and catastrophizing for child and parent
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pain trajectories
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pain criteria
Number of subjects: 144
Study: 28347290

Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 122
Study: 28347564

Group type: EXPERIMENTAL
Intervention: Walnuts (30 g/d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (450 mg/d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nuts (15 g-walnuts, 7.5 g-hazelnuts and 7.5 g-almonds/d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Statin-treated MetS patients with UM-A
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: MB patients
Number of subjects: 94
Study: 28347734

Group type: EXPERIMENTAL
Intervention: Current asthma at age 8 years (n=37)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Risk factors for current atopic asthma
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Risk factors for nonatopic asthma
Number of subjects: 127
Study: 28347955

Group type: EXPERIMENTAL
Intervention: POSS-PCU (synthetic vascular graft)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ovine left Subclavian artery (natural vascular graft)
Number of subjects: 0
Study: 28348181

Group type: EXPERIMENTAL
Intervention: Rapid PTH drop
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Gradual PTH decrease
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Slow PTH decrease with high phosphate
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Uncontrolled SHPT
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: KDIGO targets
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 269
Study: 28349167

Group type: EXPERIMENTAL
Intervention: ABT-414 (1-4 mg/kg once every 3 weeks or 1 or 1.5 mg/kg weekly for 2 out of every 3 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ABT-414 (doses ≥2 mg/kg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ABT-414
Number of subjects: 51
Study: 28349174

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study: 28349262

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (6.4 g/day for 28 days)
Number of subjects: 23
Study: 28349335

Group type: EXPERIMENTAL
Intervention: PEGylated asparaginase Oncaspar
Number of subjects: 1342
Study: 28350250

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral workshop (N = 76)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Face-to-face counseling (N = 11)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Group health talk (N = 516)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Telephone counseling (N = 39)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Overall program (all interventions combined)
Number of subjects: 642
Study: 28351230

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of spinal cord perfusion pressure (SCPP) using a pressure probe and microdialysis catheter.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) and intraspinal pressure (ISP) measurements.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal pressure reactivity index (sPRx) calculation.
Number of subjects: 0
Study: 28351310

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated, self-expanding, nitinol Stentys Stent System
Number of subjects: 70
Study: 28351345

Group type: EXPERIMENTAL
Intervention: 3 × treatment arm (three annual rounds of MDA with azithromycin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1 × treatment arm (one round of MDA)
Number of subjects: 8
Study: 28351351

Group type: EXPERIMENTAL
Intervention: Target-shooting sport intervention, practiced once a week for six months.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting list control group (no intervention).
Number of subjects: 100
Study: 28351355

Group type: EXPERIMENTAL
Intervention: Community Level Interventions for Pre-eclampsia (CLIP) intervention
Number of subjects: 32785

Group type: EXPERIMENTAL
Intervention: Community engagement sessions and training assessments of community health workers
Number of subjects: 32785

Group type: EXPERIMENTAL
Intervention: Qualitative data collection methods
Number of subjects: 32785

Group type: EXPERIMENTAL
Intervention: Data analysis methods
Number of subjects: 32785
Study: 28351364

Group type: EXPERIMENTAL
Intervention: Task-shifted cognitive-behavioral therapy (CBT) delivered by paraprofessionals
Number of subjects: 13440
Study: 28351705

Group type: EXPERIMENTAL
Intervention: Deep cartilage layer T2 change in progressor knees
Number of subjects: 74

Group type: COMPARATOR
Intervention: Deep cartilage layer T2 change in non-progressor knees
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Superficial cartilage layer T2 change in progressor knees
Number of subjects: 74

Group type: COMPARATOR
Intervention: Superficial cartilage layer T2 change in non-progressor knees
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Baseline medial femorotibial cartilage T2 in progressor knees (superficial layer)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Baseline medial femorotibial cartilage T2 in non-progressor knees (superficial layer)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Baseline medial femorotibial cartilage T2 in progressor knees (deep layer)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Baseline medial femorotibial cartilage T2 in non-progressor knees (deep layer)
Number of subjects: 74
Study: 28351831

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFOX6m + SIR-Spheres microspheres
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX6m alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy + SIRT
Number of subjects: 0
Study: 28351842

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow-derived mononuclear cells (BMCs)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Baseline hs-TnT levels
Number of subjects: 157
Study: 28351901

Group type: EXPERIMENTAL
Intervention: Patients with late gadolinium enhancement (LGE)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Patients without late gadolinium enhancement (LGE)
Number of subjects: 399
Study: 28353191

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) monotherapy
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) in combination with methotrexate (MTX)
Number of subjects: 427
Study: 28355434

Group type: EXPERIMENTAL
Intervention: Apixaban therapy
Number of subjects: 3417

Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 3417
Study: 28356179

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) sedation at a dose of 2 μg/kg/h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Natural sleep
Number of subjects: 50
Study: 28356182

Group type: EXPERIMENTAL
Intervention: Low-level continuous positive airway pressure (CPAP) at 2, 4, or 6 cm H2O
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level CPAP
Number of subjects: 0